ClinicalTrials.gg
Not yet recruitingNCT06400316Updated May 6, 2024

Muscle Wasting and Rheumatoid Arthritis Flares

An interventional study of Amino Acid Supplement in Rheumatoid Arthritis and Muscle Atrophy, sponsored by Leeds Beckett University. Not yet recruiting. Per ClinicalTrials.gov, last updated 2024-05-06.

Sponsored by Leeds Beckett University · Not applicable, Interventional, and Prevention

How we know

From the registry’s dates

  • Primary completion was expected by Dec 2024, 1 year 10 months ago, but the record still lists the study as not yet recruiting.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
40
Allocation
Randomized
Sex
All
01

Study summary

People living with Rheumatoid Arthritis (RA) often present with low muscle mass compared to their healthy counterparts. This affects their mobility, overall health and quality of life. Even though low muscle mass in RA has been recognised for decades, it is still highly prevalent and very little is known about its development, progression, and potential management.

The researchers hypothesise that flares of disease activity trigger acute events of muscle wasting due to high inflammation and reduced mobility. This is commonly observed in bed rest studies and people hospitalised for various reasons. If this holds true for RA, it would point towards a stepwise development of RC and potentially allow for time-targeted management of it.

A potential method to manage it is through the use of nutritional supplements. Specifically, amino acid supplementation (commonly used by athletes or people wanting to increase muscle mass) during and shortly after a flare may counteract some of the muscle wasting and allow for better long-term mobility and quality of life for people living with RA.

This study aims to investigate aspects of muscle health changes following a disease flare-up in people with Rheumatoid Arthritis (RA) and test potential interventions to minimise any such changes. The investigators will randomly assign participants to a standard care or a nutritional supplementation group and assess aspects of body composition, muscle health, disease activity and inflammation on five occasions over a 3-month period.

Read the detailed description

This study aims to investigate aspects of muscle health changes following a disease flare-up in people with Rheumatoid Arthritis (RA) and test potential interventions to minimise any such changes.

RA is the most common inflammatory arthritis manifesting mainly as joint swelling and pain, limiting mobility, and eventually leading to loss of functional capacity. RA also has severe extra-articular manifestations [1], affecting several tissues in the body including skeletal muscle [2]. People living with RA often present with an adverse body composition profile compared to the general population, characterised by low muscle mass at the presence of unchanged or even increased overall weight [3]. This condition, termed Rheumatoid Cachexia, may affect up to 2 out of 3 people with RA and associates with active disease, further reductions in mobility, and low quality of life [4].

While rheumatoid cachexia has been studied extensively, the course of its development, as well as potential causes or contributors to it are poorly understood. Inflammation, [5] as well as lifestyle factors, such as energy intake and physical activity, may contribute to the observed body composition changes [6].

People living with RA often experience flares of disease activity, where high levels of inflammation, cause an acute exaggeration of symptoms, leading to very low levels of mobility. This is commonly treated with corticosteroid injections which will rapidly reduce inflammation and allow the patient to regain mobility. However, that short period of high inflammatory load and low mobility may acutely affect muscle characteristics. Indeed, critically ill patients may lose up to 2% of skeletal muscle per day during the first week of hospitalisation [7]. This rapid decline in muscle health has been recently termed Acute sarcopenia (AS) by the European working group in sarcopenia and older persons (EWGSOP) [8]. Furthermore, recent work within this research team is currently under review (Aldrich et al., 2023 under review) demonstrating the rapid decline of muscle mass and quality in people suffering with various diseases. Additionally, corticosteroids themselves may further contribute to muscle wasting in RA [9]. Yet, the acute effects of flares and their treatment on muscle health in people with RA are not known.

Acute deterioration of muscle health following a flare may point towards a stepwise development of rheumatoid cachexia, i.e., bouts of acute deterioration that accumulate over time in steps rather than a continuous slow loss - which is the current understanding for the development of sarcopenia, the age-related muscle wasting. This would allow for target and potentially short-term interventions that could limit or even reverse muscle deterioration during a flare and help people with RA better maintain their functionality.

Exercise, and particularly resistance exercise, is the most effective way to increase muscle mass, strength, and quality. However, people during and shortly after a flare may not be willing to engage in such an intervention. Additional complexities around gym or home-based delivery, familiarisation, and safe execution render this a complex intervention with potentially limited applicability.

Nutritional supplementation on the other hand, is readily available, relatively cheap, and easy to administer. Specifically, for muscle health, amino acid supplementation, and particularly with leucine, has been shown to improve muscle mass and muscle function in older men and women [10]. Moreover, previous research has shown that these amino acid supplements do not suppress appetite, are well tolerated and easy to consume. Finally, recent unpublished data from this laboratory suggest that amino acid concentrations in the blood following consumption alongside a meal remain elevated vs placebo for over 2 hours. This indicates that consuming two supplements per day would provide sufficient amino acids to induce beneficial effects on muscle health.

Therefore, the aims of this investigation are:

  1. To understand the effects of acute RA flares on muscle health
  2. To assess the efficacy of amino acid supplementation vs. standard care in maintaining muscle health
02

Conditions studied

  • Rheumatoid Arthritis
  • Muscle Atrophy

Keywords

  • Rheumatoid Arthritis
  • Muscle Atrophy
03

In context

Arthritis, Rheumatoid

3,338 studies on the registry are indexed under Arthritis, Rheumatoid; 446 are open to participants now.

This study's planned enrollment of 40 is below the median of 96 across 2,226 interventional studies indexed under Arthritis, Rheumatoid.

Browse Arthritis, Rheumatoid studies →

Lead sponsor

Leeds Beckett University is the lead sponsor of 10 studies on the registry; 6 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Diagnosis of a flare of rheumatoid arthritis

Exclusion criteria

Exclusion Criteria:

  • Consultation with RA physician greater than 7 days before
  • Allergic to supplement ingredients
  • Other health conditions that affect muscle wasting; such as cancer and fibromyalgia
  • Previous joint replacement surgery within the last 6 months
  • Anyone with underlying kidney conditions
  • Currently partaking in other research projects involving treatments, exercise or nutritional interventions for rheumatoid arthritis
  • Patients who may be pregnant
  • Patients who are unable to provide their own
  • Patients who are unable to speak or understand English
  • Participants who have a diagnosis of dementia or Alzheimer's disease
  • Disabled participants who require wheelchair access
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
40 participants (estimated)

Study arms

  • No intervention
    Standard Care

    This 'control' group will receive standard care following a flare of rheumatoid arthritis.

  • Experimental
    Nutritional Supplementation

    This 'intervention' group will receive a 4-week intervention involving twice daily consumption of amino acid supplements.

    Dietary Supplement: Amino Acid Supplement

Interventions

  • Dietary supplementAmino Acid Supplement

    The intervention lasts 4-week following the rheumatoid arthritis flare. It requires twice daily consumption of amino acid supplements alongside the breakfast and lunch time meals.

    Also known as: Amino Acid Gel

06

What researchers measure

Primary outcomes

  1. Lean Tissue Mass

    Whole-body composition will be assessed by dual energy x-ray absorptiometry scans and this will provide a value for lean tissue (muscle mass) in kilograms.

    Time frame: Scans will take place at baseline and 1-week, 2-weeks, 4-weeks and 12-weeks after baseline.

Secondary outcomes

  1. Quadriceps Lean Tissue Mass

    Quadriceps lean tissue mass will be assessed by dual energy x-ray absorptiometry scans focussed in the quadriceps region. Lean tissue mass in this region will be provided in kilograms.

    Time frame: Scans will take place at baseline and 1-week, 2-weeks, 4-weeks and 12-weeks after baseline.

  2. Rectus Femoris Cross-sectional Area

    Rectus femoris will be assessed by ultrasound scans. The muscle belly will be imaged and cross-sectional area will be calculated from this image (cm2).

    Time frame: Scans will take place at baseline and 1-week, 2-weeks, 4-weeks and 12-weeks after baseline.

  3. Handgrip Strength

    Upper-body muscle strength will be assessed by handgrip dynamometry and the value will be recorded in kilograms.

    Time frame: Strength tests will take place at baseline and 1-week, 2-weeks, 4-weeks and 12-weeks after baseline.

  4. Knee Extensor Strength

    Lower-body muscle strength will be assessed on a seated knee extension resistance machine and the highest value achieved will be recorded in kilograms.

    Time frame: Strength tests will take place at baseline and 1-week, 2-weeks, 4-weeks and 12-weeks after baseline.

  5. Short Physical Performance Battery

    Muscle function will be assessed by the Short Physical Performance Battery. This battery includes measures of gait speed, lower-limb strength/functionality and balance. The score of all tests is combined to provide a total score where a higher score indicates better muscle function.

    Time frame: Muscle function tests will take place at baseline and 1-week, 2-weeks, 4-weeks and 12-weeks after baseline.

  6. Timed Up and Go

    Muscle function will be assessed by the Timed Up and Go Test. This test assesses mobility and balance. The time taken to complete standing, walking 3-metres, then returning to sit down is recorded and a shorter time indicates better functionality.

    Time frame: Muscle function tests will take place at baseline and 1-week, 2-weeks, 4-weeks and 12-weeks after baseline.

  7. 6-minute Walk Test

    Muscle function will be assessed by the 6-Minute Walk Test. This test assesses endurance and aerobic capacity. The total distance walked in 6 minutes is recorded and a higher score indicates greater aerobic capacity.

    Time frame: Muscle function tests will take place at baseline and 1-week, 2-weeks, 4-weeks and 12-weeks after baseline.

  8. Plasma Amino Acid Content

    Blood plasma amino acid content (μmol/L) will be assessed at all time points using liquid chromatography mass spectrometry.

    Time frame: Blood tests will take place at baseline and 1-week, 2-weeks, 4-weeks and 12-weeks after baseline.

  9. Serum Steroid Hormone Content

    Blood serum steroid hormone content (ng/ml) will be assessed at all time-points using liquid chromatography mass spectrometry.

    Time frame: Blood tests will take place at baseline and 1-week, 2-weeks, 4-weeks and 12-weeks after baseline.

  10. Serum Vitamin D Content

    Blood serum vitamin D content (ng/ml)will be assessed at all time-points using liquid chromatography mass spectrometry.

    Time frame: Blood tests will take place at baseline and 1-week, 2-weeks, 4-weeks and 12-weeks after baseline.

  11. Diet Recall

    Participants will be asked to recall their dietary intake over the preceding 24 hours to determine calorie intake.

    Time frame: 24-hour diet recall tests will take place at baseline and 1-week, 2-weeks, 4-weeks and 12-weeks after baseline.

  12. Physical Activity

    Physical activity habits will be assessed using the International Physical Activity Questionnaire (IPAQ) (short version). Time spent sitting, walking and exercising at various intensities will be recorded in days and hours.

    Time frame: 24-hour diet recall tests will take place at baseline and 1-week, 2-weeks, 4-weeks and 12-weeks after baseline.

  13. Physical Ability, Social Support and Interaction, Pain, Health & Mood (Quality of Life - Rheumatoid Arthritis-Specific)

    Quality of life will be assessed using the established Rheumatoid Arthritis quality of life (RAQoL) questionnaire. This will be assessed from a series of questions which will require answers ranked from 1 (very poor) to excellent (10).

    Time frame: Quality of life assessments will take place at baseline and 1-week, 2-weeks, 4-weeks and 12-weeks after baseline.

  14. Physical Function, Anxiety, Depression, Fatigue, Sleep Disturbance, Social Interaction & Pain (Quality of Life - PROMIS-29)

    Quality of life will be assessed using the Patient Reported Outcome Measures Information System (PROMIS-29) questionnaire. This will assess physical function, anxiety, depression, fatigue, sleep disturbance, ability to take part in social roles and activities, pain interference and pain intensity. All answers will be on a scale from 1 to 5 except for pain intensity which is recorded on a scale from 1 to 10. Lower scores indicate negative answers except for questions regarding physical function and pain intensity.

    Time frame: Quality of life assessments will take place at baseline and 1-week, 2-weeks, 4-weeks and 12-weeks after baseline.

07

Study locations

No study locations are listed for this record.

08

References and documents

Publications

  • Bonfiglioli KR, de Medeiros Ribeiro AC, Carnieletto AP, Pereira I, Domiciano DS, da Silva HC, Pugliesi A, Pereira LR, Guimaraes MFR, Giorgi RDN, Reis APMG, Brenol CV, Louzada-Junior P, da Cunha Sauma MFL, Radominski SC, da Mota LMH, da Rocha Castelar-Pinheiro G. Extra-articular manifestations of rheumatoid arthritis remain a major challenge: data from a large, multi-centric cohort. Adv Rheumatol. 2023 Jul 26;63(1):34. doi: 10.1186/s42358-023-00318-y. PubMed 37496102 ↗
  • Farrow M, Biglands J, Tanner S, Hensor EMA, Buch MH, Emery P, Tan AL. Muscle deterioration due to rheumatoid arthritis: assessment by quantitative MRI and strength testing. Rheumatology (Oxford). 2021 Mar 2;60(3):1216-1225. doi: 10.1093/rheumatology/keaa364. PubMed 32910153 ↗
  • Stavropoulos-Kalinoglou A, Metsios GS, Koutedakis Y, Nevill AM, Douglas KM, Jamurtas A, van Zanten JJ, Labib M, Kitas GD. Redefining overweight and obesity in rheumatoid arthritis patients. Ann Rheum Dis. 2007 Oct;66(10):1316-21. doi: 10.1136/ard.2006.060319. Epub 2007 Feb 8. PubMed 17289757 ↗
  • Efthymiou E, Grammatikopoulou MG, Gkiouras K, Efthymiou G, Zafiriou E, Goulis DG, Sakkas LI, Bogdanos DP. Time to Deal with Rheumatoid Cachexia: Prevalence, Diagnostic Criteria, Treatment Effects and Evidence for Management. Mediterr J Rheumatol. 2022 Sep 30;33(3):271-290. doi: 10.31138/mjr.33.3.271. eCollection 2022 Sep. PubMed 36531417 ↗
  • Ollewagen T, Powrie YSL, Myburgh KH, Smith C. Unresolved intramuscular inflammation, not diminished skeletal muscle regenerative capacity, is at the root of rheumatoid cachexia: insights from a rat CIA model. Physiol Rep. 2021 Nov;9(22):e15119. doi: 10.14814/phy2.15119. PubMed 34806343 ↗
  • Masuko K. Rheumatoid cachexia revisited: a metabolic co-morbidity in rheumatoid arthritis. Front Nutr. 2014 Nov 24;1:20. doi: 10.3389/fnut.2014.00020. eCollection 2014. PubMed 25988122 ↗
  • Fazzini B, Markl T, Costas C, Blobner M, Schaller SJ, Prowle J, Puthucheary Z, Wackerhage H. The rate and assessment of muscle wasting during critical illness: a systematic review and meta-analysis. Crit Care. 2023 Jan 3;27(1):2. doi: 10.1186/s13054-022-04253-0. PubMed 36597123 ↗
  • Cruz-Jentoft AJ, Bahat G, Bauer J, Boirie Y, Bruyere O, Cederholm T, Cooper C, Landi F, Rolland Y, Sayer AA, Schneider SM, Sieber CC, Topinkova E, Vandewoude M, Visser M, Zamboni M; Writing Group for the European Working Group on Sarcopenia in Older People 2 (EWGSOP2), and the Extended Group for EWGSOP2. Sarcopenia: revised European consensus on definition and diagnosis. Age Ageing. 2019 Jan 1;48(1):16-31. doi: 10.1093/ageing/afy169. Erratum In: Age Ageing. 2019 Jul 1;48(4):601. doi: 10.1093/ageing/afz046. PubMed 30312372 ↗
  • Lemmey AB, Wilkinson TJ, Perkins CM, Nixon LA, Sheikh F, Jones JG, Ahmad YA, O'brien TD. Muscle loss following a single high-dose intramuscular injection of corticosteroids to treat disease flare in patients with rheumatoid arthritis. Eur J Rheumatol. 2018 Sep;5(3):160-164. doi: 10.5152/eurjrheum.2018.17148. Epub 2018 Apr 2. PubMed 30071930 ↗
  • Ispoglou T, White H, Preston T, McElhone S, McKenna J, Hind K. Double-blind, placebo-controlled pilot trial of L-Leucine-enriched amino-acid mixtures on body composition and physical performance in men and women aged 65-75 years. Eur J Clin Nutr. 2016 Feb;70(2):182-8. doi: 10.1038/ejcn.2015.91. Epub 2015 Jun 17. PubMed 26081485 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No — Participant data will be anonymised and kept within the current research group. Participant data will not be shared with other researchers.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for May 2024; primary completion for Dec 2024, 7 months later.

Of 293 non-industry interventional studies with no phase under Arthritis, Rheumatoid, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 39. This study's planned 7 months is below that.

Counting every sponsor, half of 349 studies reached it within 27 months; a quarter within 13 and three quarters within 47.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 4, 2024
First posted
May 6, 2024
StartEst.
May 13, 2024
Primary completionEst.
Dec 31, 2024
CompletionEst.
Dec 31, 2024
Last update
May 6, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 6, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06400316
Lead sponsor
Leeds Beckett University
Responsible party
Sponsor
First posted
May 6, 2024
Start date
May 13, 2024 (estimated)
Primary completion
Dec 31, 2024 (estimated)
Completion
Dec 31, 2024 (estimated)
Last update
May 6, 2024

Study contacts

Luke Aldrich, MSc
Contact
L.Aldrich@leedsbeckett.ac.uk
0113 812 5180 ext. +44
Antonis Stavropoulos-Kalinoglou, PhD
Contact
a.stavropoulos@leedsbeckett.ac.uk
01138124298 ext. +44
Theocharis Ispoglou, PhD
study chair · Leeds Beckett University
Oliver Wilson, PhD
study chair · Leeds Beckett University

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in May 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion